Barclays Upgrades Momenta Pharmaceuticals (MNTA) to Overweight
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Barclays upgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Equalweight to Overweight with a price target of $19.00 (from $13.00).
Shares of Momenta Pharmaceuticals closed at $11.77 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Upgrades CVR Refining (CVRR) to Outperform; Most Exposed to RINs
- JPMorgan Upgrades Eaton Corporation (ETN) to Overweight
- Sidoti Upgrades Nu Skin Enterprises (NUS) to Buy
Create E-mail Alert Related CategoriesHot Upgrades, Upgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!